VBI Vaccines (VBIV) News Today → Shocking: One AI startup's revenue could surge 4,735% (From Manward Press) (Ad) Free VBIV Stock Alerts $0.63 -0.02 (-3.02%) (As of 05/17/2024 08:54 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20 at 3:26 AM | americanbankingnews.comVBI Vaccines (NASDAQ:VBIV) Now Covered by Analysts at StockNews.comMay 15, 2024 | investorplace.comVBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024May 15, 2024 | businesswire.comVBI Vaccines Reports First Quarter 2024 Financial ResultsMay 12, 2024 | americanbankingnews.comVBI Vaccines (NASDAQ:VBIV) Earns Sell Rating from Analysts at StockNews.comApril 16, 2024 | businesswire.comVBI Vaccines Reports Full Year 2023 Financial ResultsApril 11, 2024 | businesswire.comVBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 11, 2024 | investing.comVBI Vaccines secures $2 million in direct offeringApril 9, 2024 | businesswire.comVBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 3, 2024 | businesswire.comVBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent GlioblastomaApril 2, 2024 | msn.comVBI Vaccines expands collaboration with Canadian governmentApril 2, 2024 | businesswire.comVBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine PlatformMarch 31, 2024 | finance.yahoo.comVBI Vaccines Inc. (VBIV)March 22, 2024 | finance.yahoo.comBrii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial ResultsFebruary 15, 2024 | bizjournals.comNorth Carolina biotech inks $30M deal to expand its global pipelineFebruary 14, 2024 | msn.comVBI signs deal to sell manufacturing capabilities, certain assets with Brii BiosciencesFebruary 14, 2024 | finance.yahoo.comStrategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI VaccinesFebruary 14, 2024 | benzinga.comWhy Robinhood Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving PremarketFebruary 14, 2024 | finance.yahoo.comVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii BiosciencesFebruary 14, 2024 | businesswire.comVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii BiosciencesFebruary 13, 2024 | markets.businessinsider.comBrii Biosciences To Buy VBI's IP Rights In BRII-179February 13, 2024 | prnewswire.comBrii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial SuppliesFebruary 7, 2024 | msn.comVBI Vaccines Secures Forbearance Agreement ExtensionsNovember 20, 2023 | finance.yahoo.comVBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual MeetingNovember 14, 2023 | msn.comVBI Vaccines Non-GAAP EPS of -$0.38, revenue of $6.62M misses by $6.63MNovember 14, 2023 | finance.yahoo.comVBI Vaccines Reports Third Quarter 2023 Financial ResultsOctober 26, 2023 | finance.yahoo.comVBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine ProgramSeptember 30, 2023 | yahoo.comThese Are the Side Effects You Can Expect From the New COVID Vaccine, According to ImmunologistsSeptember 27, 2023 | msn.comVBI Vaccines’ pan-coronavirus vaccine candidate produced broad protection against COVID variants of concernSeptember 27, 2023 | markets.businessinsider.comVBI Vaccines To Advance Coronavirus Vaccine ProgramSeptember 27, 2023 | finance.yahoo.comVBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of ConcernSeptember 7, 2023 | finance.yahoo.comVBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBMSeptember 6, 2023 | msn.comVBI Vaccines gains after Phase 2 data for Hep B candidateSeptember 6, 2023 | finance.yahoo.comVBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis BAugust 14, 2023 | seekingalpha.comVBI Vaccines GAAP EPS of -$5.05 misses by $2.89, revenue of $0.74M misses by $0.19MAugust 14, 2023 | finance.yahoo.comVBI Vaccines Reports Second Quarter 2023 Financial ResultsJuly 24, 2023 | finance.yahoo.comVBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common SharesJuly 19, 2023 | finance.yahoo.com7 Biotech Stocks to Sell in JulyJuly 10, 2023 | bizjournals.comDurham biotech secures global rights to hepatitis B treatmentJuly 6, 2023 | msn.comVBI Vaccines Stock Cut in Half after Announcing Public OfferingJuly 6, 2023 | finance.yahoo.comVBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct OfferingJuly 6, 2023 | investorplace.comWhy Is VBI Vaccines (VBIV) Stock Down 40% Today?July 6, 2023 | benzinga.comBrii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to CureJuly 6, 2023 | msn.comVBI Vaccines, Brii Biosciences Expand Hepatitis B Immunotherapy PactJuly 5, 2023 | seekingalpha.comVBI Vaccines down 3% after hours on public offeringJuly 5, 2023 | businesswire.comVBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus ...July 5, 2023 | finance.yahoo.comVBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus RoyaltiesJuly 5, 2023 | finance.yahoo.comVBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and WarrantsJune 25, 2023 | finance.yahoo.comBrii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023June 15, 2023 | finance.yahoo.comVBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in AdultsJune 7, 2023 | finance.yahoo.comVBI Vaccines Announces Poster Presentation at EASL 2023 Get VBI Vaccines News Delivered to You Automatically Sign up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter. Email Address Must-See: Elon’s New Invention is Absolutely Insane (Ad)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone. Click here for the full story… VBIV Media Mentions By Week VBIV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VBIV News Sentiment▼-0.870.42▲Average Medical News Sentiment VBIV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VBIV Articles This Week▼31▲VBIV Articles Average Week Get VBI Vaccines News Delivered to You Automatically Sign up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Galecto News Today Aytu BioPharma News Today Sol-Gel Technologies News Today Indaptus Therapeutics News Today GlycoMimetics News Today Cocrystal Pharma News Today Minerva Neurosciences News Today Talphera News Today KALA BIO News Today NeuroBo Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VBIV) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VBI Vaccines Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
